Trismethoxyresveratrol

Trismethoxyresveratrol

SCHEMBL918740

COc1ccc(C=Cc2cc(OC)cc(OC)c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 6/20 1.00
CYP1B1 Q16678 6/20 1.00
ESR1 P03372 4/20 1.00
NQO2 P16083 4/20 1.00
PTGS2 P35354 3/20 1.00
AHR P35869 3/20 1.00
CYP1A2 P05177 3/20 1.00
ABL1 P00519 2/20 1.00
TTR P02766 2/20 1.00
ABCB1 P08183 2/20 1.00
ALOX5 P09917 2/20 1.00
BCR P11274 2/20 1.00
CYP19A1 P11511 2/20 1.00
TUBB1 Q9H4B7 2/20 1.00
TUBB4A P04350 1/20 1.00
TUBB P07437 1/20 1.00
TUBA3C P0DPH7 1/20 1.00
TUBA1B P68363 1/20 1.00
TUBA4A P68366 1/20 1.00
TUBB4B P68371 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trismethoxyresveratrol SCHEMBL918739 1.00 CYP1A1 (1.00) CYP1A1CYP1B1ESR1NQO2PTGS2
8Z-3,4',5-Trimethoxystilbene SCHEMBL1006207 1.00 CYP1A1 (1.00) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL13443549 0.95 CYP1A1 (0.91) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL3758141 0.95 CYP1A1 (0.91) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL5809462 0.91 CYP1A1 (0.84) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL5809455 0.91 CYP1A1 (0.84) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL9177232 0.91 TUBB1 (0.83) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL13790336 0.88 RELA (0.81) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL1743365 0.88 CYP1A1 (1.00) CYP1A1CYP1B1ESR1NQO2PTGS2
SCHEMBL4881152 0.88 RELA (0.81) CYP1A1CYP1B1ESR1NQO2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4615506-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES Sahin, Fikret (TR) 2025-09-17 EP claimed
WO-2024258363-A1 USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES SAHIN FIKRET (TR) 2024-12-19 WO claimed
CN-114796470-A Resveratrol compound and CAR-T cell targeting NKG2D ligand combined preparation of medicine for treating malignant tumor 深圳宾德生物技术有限公司 2022-07-29 CN claimed
CN-108689805-B Preparation method of resveratrol 荆楚理工学院 2021-08-03 CN claimed
CN-212017801-U Device for obtaining trans-3, 4', 5-trimethoxystilbene through condensation reaction 江苏惠利生物科技有限公司 2020-11-27 CN claimed
WO-2018210880-A1 STILBENES FOR PRE-HARVEST TREATMENT AND CROP PROTECTION EVOLVA SA (CH) 2018-11-22 WO claimed
EP-2679243-B1 Co-precipitate of one or more stilbene polyphenols in lamellar anionic solids, it's applications and related preparation method FIORETTI BERNARD (IT) 2017-05-24 EP claimed
US-20170087116-A1 Treatment of Inflammatory and Infectious Skin Disorders THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-03-30 US claimed
US-20160215306-A1 METHOD FOR PRODUCING MODIFIED RESVERATROL EVOLVA SA (CH) 2016-07-28 US claimed
EP-3039132-A2 A METHOD FOR PRODUCING MODIFIED RESVERATROL Evolva SA (CH) 2016-07-06 EP claimed
WO-2009105123-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING DISEASES THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2009-08-27 WO claimed
WO-2008103916-A2 COMPOSITIONS AND METHODS FOR TREATING CANCER OR A NEUROTROPHIC DISORDER THE TRUSTEES OF COLUMBIA UNIVERISTY IN THE CITY OF NEW YORK (US) 2008-08-28 WO claimed
EP-1654210-B1 STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS SZEKERES THOMAS (AT) 2008-07-30 EP claimed
US-20080166304-A1 Inactivation of Microorganisms With Multidrug Resistance Inhibitors and Phenothiaziniums THE GENERAL HOSPITAL CORPOARTION (US) 2008-07-10 US claimed
US-20080139650-A1 Fungicidally Active Polymer Dispersions And Use Thereof CELANESE EMULSIONS GMBH (DE) 2008-06-12 US claimed
WO-2008070872-A1 PREVENTION AND TREATMENT OF COLON CANCER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2008-06-12 WO claimed
WO-2006034219-A2 INACTIVATION OF MICROORGANISMS WITH MULTIDRUG RESISTANCE INHIBITORS AND PHENOTHIAZINIUMS THE GENERAL HOSPITAL CORPORATION (US) 2006-03-30 WO claimed
WO-2003031381-A2 SYNTHESIS OF (Z)-3,5,4'-TRIMETHOXYSTILBENE, AND USE THEREOF UNIVERSITE LOUIS PASTEUR (FR) 2003-04-17 WO claimed
US-20020028852-A1 Resveratrol analogs for prevention of disease RUTGERS, THE STATE UNIVERSITY 2002-03-07 US claimed
WO-2001021165-A1 RESVERATROL ANALOGS FOR PREVENTION OF DISEASE RUTGERS, THE STATE UNIVERSITY (US) 2001-03-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139650-A1 Fungicidally Active Polymer Dispersions And Use Thereof CBR3, CBR1, CYP3A4 CYP1A1 5/4885CYP1B1 4/4885ESR1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.